公司簡介
———— 創新第一 誠信至上 ————
優質、高效,用心服務為客戶
揚州市欽源醫藥科技有限公司位于富饒的古城揚州,依托于揚州化學工業園區和揚州高校,以全球醫藥市場需求為導向。專業從事原料藥產品的研發、銷售,定制合成,雜質對照品制備,技術轉讓及醫藥中間體開發(工藝優化小試、中試以及大生產)等業務。我們的產品主要包括手性化合物,雜環化學物,醫藥中間體和原料藥。查看詳情 >>
新聞資訊
—專業從事原料藥產品的研發、銷售,定制合成 —
Beware of drug driving a...
Medicated driving usually refers to the driver taking certain medications that may affect safe driving The phenomenon of driving still after taking certain drugs can lead to adverse reactions such as drowsiness, dizziness, and blurred vision, which will affect driving safety.
China's first technologi...
On the 3rd, the reporter learned from Yichang Humanwell Pharmaceutical Co., Ltd., located in Yichang City, Hubei Province, that the company has officially signed an agreement with Indonesia MBF on the export project of narcotic drugs technology.
Selumetinib (AZD6244), M...
Selumetinib (AZD6244, ARRY-142886) is a small molecule MEK inhibitor developed by Array BioPharma in the United States. MEK1IC5014 nmol/L, molecular weight 458.
Trametinib -- a new drug...
Trametinib is a new drug developed by GSK plc to treat Melanoma. It is a MEK inhibitor. In 2013, it was approved by the US FDA for marketing. As a single drug oral tablet, MEKINIST is suitable for carrying BRAF V600E or V600K mutations
產品介紹
——醫藥中間體/醫藥原料藥/定制合成歡迎選購 ——
ABOUT US
———————— Innovation First Integrity First ————————
Yangzhou Qinyuan Pharmaceutical Technology Co., Ltd --Specializing in the research and development, sales, and customized synthesis of raw material pharmaceutical products
Yangzhou Qinyuan Pharmaceutical Technology Co., Ltd. is located in the fertile ancient city of Yangzhou, relying on Yangzhou Chemical Industry Park and Yangzhou universities, and guided by the demand of the global pharmaceutical market. Specializing in the research and development, sales, customized synthesis, preparation of impurity reference materials, technology transfer, and development of pharmaceutical intermediates (process optimization pilot, pilot, and large-scale production) of API products. Our products mainly include chiral compounds, heterocyclic chemicals, pharmaceutical intermediates, and raw materials. Detail >>
Enterprise Vision
Yangzhou Qinyuan Pharmaceutical Technology Co., Ltd. is developing towards collectivization, internationalization, technologization, humanization, and modernization.
Facing the future of chemical medicine, our company will fulfill its social responsibility and create a first-class pharmaceutical company.
Products
———————— Our product series: pharmaceutical intermediates/pharmaceutical raw materials/customized synthesis Welcome to purchase ————————
News
———————— Specializing in the research and development, sales, and customized synthesis of raw material pharmaceutical products ————————
Beware of drug driving after taking four types of drugs
Medicated driving usually refers to the driver taking certain medications that may affect safe driving The phenomenon of driving still after taking certain drugs can lead to adverse reactions such as drowsiness, dizziness, and blurred vision, which will affect driving safety.
China's first technological export of narcotic drugs
On the 3rd, the reporter learned from Yichang Humanwell Pharmaceutical Co., Ltd., located in Yichang City, Hubei Province, that the company has officially signed an agreement with Indonesia MBF on the export project of narcotic drugs technology.
Selumetinib (AZD6244), MEK inhibitor
Selumetinib (AZD6244, ARRY-142886) is a small molecule MEK inhibitor developed by Array BioPharma in the United States. MEK1IC5014 nmol/L, molecular weight 458.
Trametinib -- a new drug for Melanoma
Trametinib is a new drug developed by GSK plc to treat Melanoma. It is a MEK inhibitor. In 2013, it was approved by the US FDA for marketing. As a single drug oral tablet, MEKINIST is suitable for carrying BRAF V600E or V600K mutations
Enterprise Style
———————— Mainly producing chiral compounds, heterocyclic chemicals, pharmaceutical intermediates and raw materials ————————
企業風貌
——主要生產手性化合物,雜環化學物,醫藥中間體和原料藥 ——